Low-Dose aspirin, coxibs, and other NSAIDS: A clinical mosaic emerges

Molecular Interventions

Volumn 9, Issue 1, 2009, Pages 31-39

  Patrono, Carlo ^a   Baigent, Colin ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARACHIDONIC ACID METABOLISM; CARDIOVASCULAR EFFECT; DRUG MECHANISM; ENDOTHELIUM; ENZYME INHIBITION; REVIEW; THROMBOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 63749128221     PISSN: 15340384     EISSN: 15432548     Source Type: Journal    
DOI: 10.1124/mi.9.1.8     Document Type: Review

References (48)

1. Burke, A., Smyth, E., and FitzGerald, G.A. Analgesic-Antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton, L., Lazo, J., Parker, K., Buxton, I., and Blumenthal, D. eds) pp 673-715, McGraw-Hill, New York (2006).
2. FitzGerald, G.A. and Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442 (2001).
3. Patrono, C., Patrignani, P., and Garcia Rodriguez, L.A. Cyclooxygenase- selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 108, 7-13 (2001).
4. Grosser, T., Fries, S., and FitzGerald, G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 116, 4-15 (2006).
5. Patrono, C., Garcia Rodriguez, L.A., Landolfi, R., and Baigent, C. Low- dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353, 2373-2383 (2005).
6. Rocca, B., Secchiero, P., Ciabattoni, G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc. Natl. Acad. Sci. USA 99, 7634-7639(2002).
7. Davi, G. and Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494, (2007).
8. Patrono, C., Ciabattoni, G., Pugliese, F., Pierucci, A., Blair, I.A., and FitzGerald, G.A. Estimated rate of thromboxane secretion into the circulation of normal man. J. Clin. Invest. 77, 590-594 (1986).
9. Reilly, I.A. and FitzGerald, G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69, 180-186 (1987).
10. Santilli, F., Rocca, B., De Cristofaro, R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. Implications for aspirin "resistance." J. Am. Coll. Cardiol. 53, 667-677 (2009).
11. Jaffe, E.A. and Weksler, B.B. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J. Clin. Invest. 63, 532-535 (1979).
12. FitzGerald, G.A., Brash, A.R., Falardeau, P. and Oates, J.A. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest. 68, 1272-1276 (1981).
13. FitzGerald, G.A., Smith, B., Pedersen, A.K., and Brash, A.R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310, 1065-1068 (1984).
14. Moncada, S. and Vane, J.R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N. Engl. J. Med. 300, 1142-1147 (1979).
15. Majerus, P.W. Arachidonate metabolism in vascular disorders. J. Clin. Invest. 72, 1521-1525 (1983).
16. Murata, T., Ushikubi, F., Matsuoka, T. et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682 (1997).
17. Cheng, Y., Austin, S.C., Rocca, B., Koller, B.H., Coffman, T.M., Grosser, T., Lawson, J.A., and FitzGerald, G.A. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539-541 (2002).
18. Cullen, L., Kelly, L., Connor, S.O., and Fitzgerald, D.J. Selective cycloox- ygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 287, 578-582 (1998).
19. McAdam, B.F., Catella-Lawson, F., Mardini, I.A., Kapoor, S., Lawson, J.A., and FitzGerald, G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl. Acad. Sci. USA 96, 272-277 (1999).
20. Catella-Lawson, F., McAdam, B., Morrison, B.W. et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289, 735-741 (1999).
21. Topper, J.N., Cai, J., Falb, D., and Gimbrone, M.A. Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl. Acad. Sci. USA 93, 1041710422 (1996).
22. Warner, T.D. and, Mitchell, J.A. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 371, 270-273 (2008).
23. Patrignani, P., Panara, M.R., Greco, A. et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271, 1705-1712 (1994).
24. Garcia Rodriguez, L.A., Tacconelli, S., and Patrignani, P. Role of dose- potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population J. Am. Coll. Cardiol. 52, 1628-1636 (2008).
25. Cheng, Y., Wang, M., Yu, Y., Lawson, J., Funk, C.D., and Fitzgerald, G.A. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J. Clin. Invest. 116, 1391-1399 (2006).
26. Patrono, C., Baigent, C., Hirsh, J., and Roth, G. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133, 199S-233S (2008).
27. Pedersen, A.K. and FitzGerald, G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311, 1206-1211 (1984).
28. Patrignani, P., Filabozzi, P., and Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372 (1982).
29. Patrono, C., Ciabattoni, G., Patrignani, P., Filabozzi, P., Catella, F., Davi, G., and Forni, L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72, 1177-1184 (1985).
30. Capone, M.L., Tacconelli, S., Sciulli, M.G. et al. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471 (2004).
31. Capone, M.L., Tacconelli, S., Sciulli, M.G., Anzellotti, P., Di Francesco, L., Merciaro, G., Di Gregorio, P., and Patrignani, P. Human pharmacology of naproxen sodium. J. Pharmacol. Exp. Ther. 322, 453-460 (2007).
32. nd. Lawson, J.A., and Brash, A.R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest. 71, 676-688 (1983).
33. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71-86 (2002).
34. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data. Lancet (in press).
35. Bombardier, C., Laine, L., Reicin, A. et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343, 1520-1528 (2000).
36. Bresalier, R.S., Sandler, R.S., Quan, H. et al. for the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemopreven- tion trial. N. Engl. J. Med. 352, 1092-1102 (2005).
37. Solomon, S.D., McMurray, J.J., Pfeffer, M.A. et al. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
38. Kearney, P.M., Baigent, C., Godwin, J., Halls, H., Emberson, J.R., and Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrom- bosis? Meta-analysis of randomised trials. Br. Med. J. 332, 1302-1308 (2006).
39. Nussmeier, N.A., Whelton, A.A., Brown, M.T., Langford, R.M., Hoeft, A., Parlow, J.L., Boyce, S.W., and Verburg, K.M. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081-1091 (2005).
40. Solomon, S.D., Wittes, J., Finn, P.V. et al. for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117, 2104-2113 (2008).
41. Baron, J.A., Sandler, R.S., Bresalier, R.S., Lanas, A., Morton, D.G., Riddell, R., Iverson, E.R., and DeMets, D.L. Cardiovascular events associated with rofecoxib: Final analysis of the APPROVe trial. Lancet 372, 1756-1764 (2008).
42. Cannon, C.P., Curtis, S.P., FitzGerald, G.A. et al. for the MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368, 1771-1781 (2006).
43. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS. Clin. Trials. 1, e33 (2006).
44. FitzGerald, G.A. COX-2 in play at the AHA and the FDA. Trends. Pharmacol. Sci. 28, 303-307 (2007).
45. Antman, E.M., Bennett, J.S., Daugherty, A., Furberg, C., Roberts, H., and Taubert, K.A. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115, 1634-1642 (2007).
46. Scheiman, J.M. and Fendrick, A.M. Summing the risk of NSAID therapy. Lancet 369, 1580-1581 (2007).
47. Strand, V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 370, 2138-2151 (2007).
48. American College of Rheumatology ad hoc group on use of selective and nonselective nonsteroidal antiinflammatory drugs. Recommendations for use of selective and nonselective nonsteroidal anti-inflammatory drugs: an American College of Rheumatology white- paper. Arthritis Rheum. 59, 1058-1073 (2008).